Disease-associated vision changes are common in GCA, with no significant difference in visual improvement observed with IV glucocorticoids vs oral therapy.

While the trial met its primary endpoint, the FDA stated in its letter that the application could not be approved in its current form.

An AI-powered platform can advance the processing speed of data from large multi-center clinical trials.

Presbyopia-correcting intraocular lenses have lower health care burden after bilateral cataract surgery relative to ...

Investigators reviewed DNA methylation patterns and how they can aid in differential diagnoses for patients with lacrimal ...

The FDA has approved Epioxa™ HD 0.239% and Epioxa™ 0.177% for use in epithelium-on corneal collagen CXL for the treatment of ...

Researchers assessed the quality of life measures of patients with thyroid eye disease treated with Veligrotug, a full antagonist humanized mAb to IGF-1R.

Explainable artificial intelligence (XAI) can identify clinically significant diabetic retinal neurodegeneration (DRN) on ...

The study published in JAMA Ophthalmology – the first epidemiologic study to home in on eye injuries in pickleball – reviewed ...

Investigators reviewed ocular side effects of semaglutide use from a global population-based study across 180 countries.

Investigators conducted a large-scale retrospective cohort study of the prevalence and age of onset of retinal detachment and ...

Researchers compared the use of aflibercept 8 mg and 2 mg in patients with various retinal vein occlusion subtypes.